Biochemical recurrence (BCR), or an elevation in prostate-specific antigen in men after treatment for localized prostate cancer, is an early indication of clinical progression, distant metastases, and mortality. Correlations have also recently been established between diabetes and the incidence and mortality of prostate cancer. However, it remains unknown whether diabetes may predict BCR.
We performed a meta-analysis of published articles to investigate the prognostic value of diabetes for BCR in prostate cancer. Eight studies and 11,923 patients were included in our meta-analysis. The relative risk (RR) and its 95 % confidence interval (CI) were calculated.
We found no apparent association between diabetes and BCR (adjusted RR 1.04; 95 % CI 0.87-1.22).
The evidence of this meta-analysis indicates that diabetes is not a predictor of risk of BCR in patients with prostate cancer.
International urology and nephrology. 2016 May 11 [Epub ahead of print]
Qingling Hua, Yanzhe Zhu, Hu Liu, Xiaobing Ye
Department of Oncology, Yijishan Hospital of Wannan Medical College, No. 2 West Zheshan Road, Wuhu, 241001, China., Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China., Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China., Department of Oncology, Yijishan Hospital of Wannan Medical College, No. 2 West Zheshan Road, Wuhu, 241001, China. .